<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320797</url>
  </required_header>
  <id_info>
    <org_study_id>SLEFLURINOCYTE</org_study_id>
    <nct_id>NCT04320797</nct_id>
  </id_info>
  <brief_title>Urinary T Cell Biomarker for Prediction in Lupus Nephritis</brief_title>
  <official_title>Phenotype of Urinary CD4+ T Cells as Biomarkers for Prediction of Outcome in Lupus Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berlin Institute of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary T-lymphocytes may be predictive for clinical outcome in patients with lupus
      nephritis. The investigators hypothesize that the amount of CD4+ effector/memory T-cells in
      urine at time of diagnosis predicts the outcome of patients with active lupus nephritis (LN)
      after 6 months of therapy. In a prospective, six-months follow-up study patients' urine will
      be analysed by flow cytometry every 60 days (+/- 10d). Treatment will be performed to the
      discretion of the treating clinician. After 6 months of treatment response will be determined
      as either complete response or partial response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phenotype of CD4+ T cells at time point 0 predictive of clinical outcome in patients with lupus nephritis</measure>
    <time_frame>6 months</time_frame>
    <description>Urinary CD4+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with lupus nephritis. The frequency of effector/memory CD4+ T lymphocytes is higher in patients with non- or partial response.
Complete response at 24 weeks: the return to within 10 percent of normal values of serum creatinine levels, proteinuria, and urine sediment.
Partial response at 24 weeks: improvement of 50 percent in all abnormal renal measurements, without worsening - within 10 percent - of any measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distinction between proliferative LN (class III and class IV) and non-proliferative LN (classes I, II and VI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of patient with persistent renal abnormalities as partial response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of complete or partial response according to normalization of the amount of urinary T cells at time point 2 and 4</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype of CD8+ T cells at time point 0 predictive of clinical outcome in patients with lupus nephritis</measure>
    <time_frame>6 months</time_frame>
    <description>Urinary CD8+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with lupus nephritis. The frequency of effector/memory CD8+ T lymphocytes is higher in patients with non- or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of proliferative lupus nephritis in patients with systemic lupus erythematodes (SLE)</measure>
    <time_frame>6 months</time_frame>
    <description>Diagnosis according to initial T cell count</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">79</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Active lupus nephritis</arm_group_label>
    <description>Patients with proliferative lupus nephritis (Class III and IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with systemic lupus erythematodes without lupus nephritis or lupus nephritis I, II or VI</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow cytometry analysis of urine samples</intervention_name>
    <description>Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.
T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326</description>
    <arm_group_label>Active lupus nephritis</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine, lymphocytes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at medical wards of Charité Universitätsmedizin Berlin and University College
        London
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven lupus nephritis

          -  In absence of a biopsy a SLEDAI of at least 10 &amp; at least two renal elements of the
             renal SLEDAI (rSLEDAI)

          -  Informed consent

          -  Diagnosis of SLE according to the American College of Rheumatology (ACR) criteria

        Exclusion Criteria:

          -  Biopsy-proven non-SLE related disease

          -  Urinary tract infection

          -  Active menstrual bleeding

          -  Kidney transplantation during observation time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Enghard, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luka Prskalo</last_name>
    <phone>+49 17630130373</phone>
    <email>luka.prskalo@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Enghard, PD Dr. med.</last_name>
    <email>philipp.enghard@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luka Prskalo</last_name>
      <phone>+49 17630130373</phone>
      <email>luka.prskalo@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Philipp Enghard, PD Dr. med.</last_name>
      <email>philipp.enghard@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Luka Prskalo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Enghard, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free London</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Salama, PhD</last_name>
      <email>alan.salama@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Enghard P, Rieder C, Kopetschke K, Klocke JR, Undeutsch R, Biesen R, Dragun D, Gollasch M, Schneider U, Aupperle K, Humrich JY, Hiepe F, Backhaus M, Radbruch AH, Burmester GR, Riemekasten G. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann Rheum Dis. 2014 Jan;73(1):277-83. doi: 10.1136/annrheumdis-2012-202784. Epub 2013 Mar 8.</citation>
    <PMID>23475982</PMID>
  </reference>
  <reference>
    <citation>Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF 3rd, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B; Accelerating Medicines Partnership in SLE network. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019 Jul;20(7):902-914. doi: 10.1038/s41590-019-0398-x. Epub 2019 Jun 17. Erratum in: Nat Immunol. 2019 Aug 13;:.</citation>
    <PMID>31209404</PMID>
  </reference>
  <reference>
    <citation>Dolff S, Abdulahad WH, Arends S, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M. Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis. Arthritis Res Ther. 2013 Feb 27;15(1):R36. doi: 10.1186/ar4189.</citation>
    <PMID>23445537</PMID>
  </reference>
  <reference>
    <citation>Kopetschke K, Klocke J, Grießbach AS, Humrich JY, Biesen R, Dragun D, Burmester GR, Enghard P, Riemekasten G. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Res Ther. 2015 Apr 3;17:94. doi: 10.1186/s13075-015-0600-y.</citation>
    <PMID>25890061</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Philipp Enghard</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>lupus nephritis</keyword>
  <keyword>systemic lupus erythematodes</keyword>
  <keyword>urinary biomarker</keyword>
  <keyword>outcome</keyword>
  <keyword>prediction</keyword>
  <keyword>urinary effector memory T lymphocytes</keyword>
  <keyword>glomerulonephritis</keyword>
  <keyword>non-invasive biomarker</keyword>
  <keyword>flow cytometry</keyword>
  <keyword>treatment outcome</keyword>
  <keyword>CD4-positive T-lymphocytes/immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

